Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21559879 | 0.85 | ALOX15 (0.35) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL20130632 | 0.83 | ALOX15 (0.34) | ALOX15BLMPMP22KMT2ACHRNB2 | |
| SCHEMBL197386 | 0.79 | KMT2A (0.50) | ALOX15BLMPMP22KMT2ACHRNB2 | |
| SCHEMBL20099695 | 0.79 | ALOX15 (0.40) | ALOX15BLMPMP22KMT2ACHRNB2 | |
| SCHEMBL26343745 | 0.79 | GABRR1 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23037168 | 0.79 | KMT2A (0.50) | ALOX15BLMPMP22KMT2ACHRNB2 | |
| SCHEMBL197387 | 0.79 | KMT2A (0.50) | ALOX15BLMPMP22KMT2ACHRNB2 | |
| SCHEMBL14962057 | 0.76 | CPB2 (0.34) | DPP4DPP8DPP9 | |
| SCHEMBL20130638 | 0.76 | ALOX15 (0.38) | ALOX15BLMPMP22KMT2ACHRNB2 | |
| SCHEMBL7748931 | 0.74 | CHRNB2 (0.39) | ALOX15BLMPMP22KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640544-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640544-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | ALOX15 2953/4885BLM 4719/4885PMP22 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.